Rapid, non-genomic actions of Retinoic Acid on Phosphatidyl-Inositol-3-Kinase by Masiá, Susana et al.
  
 
 
 
Rapid, non-genomic actions of Retinoic Acid on Phosphatidyl-Inositol-3-Kinase 
signaling pathway mediated by the Retinoic Acid Receptor 
 
Short title: RA-induced activation of PI3K 
 
 
 
Susana Masiá1, Susana Alvarez2, Angel R. de Lera2, and Domingo Barettino1, 3 
 
1
 Biology of Hormone Action Unit. Dept. of Molecular and Cellular Pathology and 
Therapy. Instituto de Biomedicina de Valencia (CSIC). Jaime Roig, 11. E-46010 Valencia, 
Spain. 
 
2
 Universidade de Vigo, Departamento de Química Orgánica; Facultad de Ciencias, E-
36200 Vigo, Spain. 
 
3
 Corresponding author: Dr. Domingo Barettino. Instituto de Biomedicina de Valencia 
(CSIC). Jaime Roig, 11. E-46010 Valencia (Spain). 
Tel: +34-963 391 769 
FAX: +34-963 690 800 
E_mail: dbarettino@ibv.csic.es  
 
 
Disclosure Statement: The authors have nothing to disclose. 
 
 
 
 2 
ABSTRACT 
 
Retinoic Acid (RA) treatment of SH-SY5Y neuroblastoma cells results in activation of 
phosphatidyl-inositol-3-kinase (PI3K) signaling pathway, and this activation is required for 
RA-induced differentiation. Here we show that RA activates PI3K and ERK1/2 MAP Kinase 
signaling pathways through a rapid, non-genomic mechanism that does not require new gene 
transcription or newly synthesized proteins. Activation of PI3K by RA appears to involve the 
classical nuclear receptor RAR, on the basis of the pharmacological profile of the activation, 
loss and gain of function experiments with MEF-RAR(αβγ)L-/L- null cells, and the physical 
association between liganded RAR and PI3K kinase activity. The association of RAR with the 
two subunits of PI3K was differentially regulated by the ligand. Immunoprecipitation 
experiments performed in SH-SY5Y cells showed stable association between RARα and p85, 
the regulatory subunit of PI3K, independently of the presence of RA. In contrast, ligand 
administration increased the association of p110, the catalytic subunit of PI3K, to this 
complex. The intracellular localization of RAR resulted to be relevant for PI3K activation. A 
chimerical RAR receptor fusing c-Src myristylation domain to the N-terminal of RARα (Myr-
RARα) was targeted to plasma membrane. Transfection of Myr-RARα to MEF-RAR(αβγ)L-/L- 
null cells and COS-7 cells results in strong activation of PI3K signaling pathway, although 
both in the absence as well in the presence of RA. Our results support a mechanism in which 
ligand binding to RAR would play a major role in the assembly and intracellular location of a 
signaling complex involving RAR and the subunits of PI3K.  
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INTRODUCTION 
 
 Retinoic Acid (RA), the biologically 
active form of Vitamin A, plays a major role 
as physiological regulator of important 
biological processes, as the early embryonic 
development, the development of certain 
organs and systems, etc. (1). RA is an 
important signaling molecule for the 
development of the nervous system, especially 
by controlling proliferation and differentiation 
of neural cells (2, 3). The actions of RA and its 
derivatives are mediated by two types of 
receptors, RARs and RXRs, belonging to the 
Nuclear Hormone Receptor superfamily, 
which encompasses receptors for steroid and 
thyroid hormones, vitamins A and D, and 
many other signaling molecules (4). Nuclear 
hormone receptors have been traditionally 
considered as ligand-regulated transcription 
factors, acting through binding to specific 
DNA elements on the promoters of target 
genes and ultimately leading to changes in the 
expression levels of those genes. However, 
novel non-genomic mechanisms of signal 
transduction through nuclear hormone 
receptors have been described. These rapid, 
non-genomic actions do not rely on gene 
transcription or protein synthesis, but involve 
ligand-induced modulation of signal 
transduction pathways (5-8).  
Administration of RA to 
neuroblastoma cells in vitro leads to 
proliferative arrest and neuronal differentiation 
(9-11). These results prompted the 
introduction of RA and its derivatives into 
therapeutic protocols for neuroblastoma 
patients, with success especially in the 
treatment of minimal residual disease (12, 13). 
In a previous paper we have described that RA 
treatment of SH-SY5Y neuroblastoma cells 
results in activation of phosphatidyl-inositol-3-
kinase (PI3K) signaling pathway, and this 
activation is required for RA-induced 
differentiation (14). Although the mechanisms 
by which RA regulates gene transcription are 
well understood, very little is known about the 
molecular mechanisms underlying the 
activation of PI3K/Akt signaling pathway by 
RA. We report here that activation of PI3K by 
RA occurs through a non-genomic action of 
the classical nuclear RA receptor RAR. In 
contrast to what has been reported for steroid 
receptors, where interaction of the receptor 
with the regulatory subunit of PI3K (p85) was 
under the control of ligand, (15-17) we show 
that RAR forms a stable complex with p85-
PI3K. Activation of PI3K by ligand-bound 
RAR is mediated by a novel mechanism in 
which the binding of RAR by its cognate 
ligand results in the formation of a signaling 
complex by recruiting the catalytic subunit of 
PI3K. In addition, the experiments shown here 
suggest a role for RA in regulating the 
intracellular location of that complex including 
RAR and the two subunits of PI3K.  
 
RESULTS 
 
Rapid, non-genomic activation of PI3K and 
ERK1/2 MAP kinase pathways by RA.  
 
Administration of RA to SH-SY5Y 
neuroblastoma cells results in activation of 
PI3K signaling pathway (14). When this 
phenomenon was analyzed in its right 
timeframe, we observed that RA rapidly 
activated PI3K signaling pathway, and specific 
phosphorylation of Akt kinase in Ser473 could 
be detected within 5 min of RA treatment (Fig. 
1A). Rapid activation of PI3K signaling 
pathway by RA argued for an atypical, non-
genomic activation event and against a 
classical transcriptional action of RA. In fact, 
RA treatment could induce phosphorylation of 
Akt kinase in the absence of newly 
synthesized proteins in Cycloheximide-treated 
cells as well in the absence of new 
transcription in Actinomycin D-treated cells 
(Fig. 1B). Activation of signaling pathways by 
RA is not limited to PI3K/Akt, but also the 
ERK1/2 MAP Kinase pathway was rapidly 
activated in RA-treated neuroblastoma cells, as 
detected by western blot with phosphorylation-
specific ERK1/2 antibodies (Fig. 1C).  
Rapid activation of signaling pathways 
by RA appeared not restricted to 
neuroblastoma cells. Mouse embryo fibroblast 
NIH-3T3 cells expressed considerable 
amounts of RARγ (Fig. 2A), and responded to 
RA treatment by activating PI3K (Fig. 2B) and 
ERK1/2 (Fig. 2D) signaling pathways (see 
also (18)). Activation of PI3K signaling 
pathway in response to RA treatment occurred 
both in serum-deprived NIH-3T3 cells (Fig. 
2B), as well in cells growing in the presence of 
10% newborn calf serum (Fig. 2C). Although 
in serum-fed cells Akt phosphorylation basal 
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levels were higher than in serum-starved cells, 
RA treatment resulted in increased Akt 
phosphorylation (Fig 2C). As was the case for 
neuroblastoma cells, activation of PI3K by RA 
in NIH-3T3 cells was not prevented by 
Cycloheximide or Actinomycin D treatments. 
As expected, RA-induced phosphorylation of 
Akt was impaired by treatment with the 
specific PI3K inhibitor LY294002 (Fig. 2C).  
 
Involvement of nuclear receptor RAR in 
RA-induced rapid non-genomic activation 
of PI3K. 
 
 The first type of evidence supporting 
the involvement of the nuclear RA receptor 
RAR in RA-induced non-genomic actions 
came out from the pharmacological features of 
the activation of PI3K by RA in 
neuroblastoma cells. First, the concentrations 
of RA required for activation of PI3K 
signaling pathway (as low as 10 nM, see Fig. 
3A) are compatible with the observed Kd of 
RARs for RA in the nanomolar range. (19) 
Second, all the different RAR ligands tested up 
to now, including RAR-specific synthetic 
retinoids, have been able to activate PI3K 
similarly to all trans-RA. As shown in Figure 
3B, both natural and synthetic RAR-selective 
agonists (all-trans-RA, 13-cis-RA, TTNPB, 
Am580, 4-HPR, and ALRT1550) as well as 
pan-RAR agonists (9-cis-RA and LG 100567) 
induced phosphorylation of Akt in Ser473 (Fig. 
3B). Next, we tested whether the activation of 
PI3K signaling pathway by RA or a RAR-
selective agonist like TTNPB could be 
prevented by the pan-RAR antagonist 
AGN193109 (20). Surprisingly, treatment of 
cells with AGN193109 (5 µM) could not block 
the activation of PI3K by RA or TTNPB (0.5 
µM). Moreover, AGN193109 itself act as an 
agonist and activated Akt phosphorylation 
(Fig. 3C). However, in the same 
concentrations AGN193109 prevented RA-
induced transcriptional activation of RARB, 
one of the prominent RA–regulated genes in 
neuroblastoma cells, as shown by Northern 
Blot hybridization (Fig. 3D). Therefore, 
AGN193109 showed a dissociated 
antagonist/agonist profile, having a potent 
transcriptional antagonistic activity, but acting 
as an agonist in respect to PI3K activation.  
 The second type of evidence 
supporting the involvement of nuclear RA 
receptor RAR in the activation of PI3K was 
obtained by loss and gain of function 
experiments. Cultured mouse embryo 
fibroblasts from wild-type animals (MEF-wt 
cells) responded to RA treatment by activating 
PI3K/Akt pathway (Fig. 4A). However, 
activation of PI3K/Akt pathway by RA was 
abolished in a mouse embryo fibroblast cell 
line devoid of all the tree RAR isoforms, 
named MEF(RARαβγ)L-/L- (21) (Fig. 4B). Re-
introduction of a functional RARα gene 
through a retroviral expression vector resulted 
in restoration of RA-induced PI3K/Akt 
activation (Fig. 4C).  
A third type of evidence supporting 
the involvement of RAR in RA-induced 
activation of PI3K/Akt signaling pathway was 
obtained by assaying PI3K activity on 
immunoprecipitated fractions of control and 
RA-treated SH-SY5Y cells (Figure 5). Anti-
RARα immunoprecipitated fractions were 
assayed together with anti-PI3K-p110 
immunoprecipitates as positive control and 
control IgG immunoprecipitates as negative 
control. PI3K activity could be detected 
associated to RARα immunocomplexes only 
in RA-treated cells, whereas no activity above 
background levels was detected in RARα-
immunoprecipitated fractions from untreated 
cells.  
All these experiments together 
strongly support a role for the classical RA 
nuclear receptor RAR in rapid, non-genomic 
activation of PI3K signaling pathway by RA.  
 
Ligand differentially regulates the 
association between RAR and PI3K 
subunits  
 
The kinase assays performed on 
immunoprecipitates shown in Figure 5 suggest 
the idea of a physical association between 
RAR and PI3K that could be regulated by 
ligand binding to RAR, and prompted us to 
analyze the interactions of the PI3K subunits 
with RAR in SH-SY5Y neuroblastoma cells. 
Surprisingly, immunoprecipitation 
experiments followed by Western blot 
detection demonstrated the existence of a 
stable physical interaction between RARα and 
p85 regulatory subunit of PI3K in SH-SY5Y 
neuroblastoma cells. Antibodies against RARα 
immunoprecipitated p85-PI3K from SH-SY5Y 
cell extract, but not an irrelevant antibody used 
as control (Fig. 6A). Conversely, a p85-PI3K 
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antiserum immunoprecipitated RARα (Fig. 
6B). However, association of p85 and RARα 
was observed independently of the presence of 
RA (Fig. 6A and 6B). This association could 
be detected in the cell nucleus, as 
demonstrated by immunoprecipitation 
experiments carried out in nuclear extracts 
(Fig. 6C). In contrast, RA-induced association 
of p110-PI3K to RARα was observed in 
immunoprecipitates from RARα antibodies 
(Fig. 6A). Immunoprecipitation experiments 
with an antibody against p110-PI3K showed 
association between p110, p85 and RARα, and 
ligand binding increased notably complex 
formation between p110 and p85 and RARα 
(Fig. 6D). Taken together, the results of the 
immunoprecipitation experiments support the 
idea of a stable complex between RARα and 
p85, the regulatory subunit of PI3K. Ligand 
binding to RAR would facilitate the formation 
of a signaling complex, by increasing the 
association of the p110 catalytic subunit of 
PI3K.  
We wanted to know whether a direct 
protein-protein interaction determines the 
association between RAR and p85-PI3K. This 
was tested in vitro by GST pull-down assay, 
using recombinant GST-RARα fusion protein 
expressed in E. coli and extracts from cells 
overexpressing p85-PI3K tagged with the HA 
epitope. As shown in Figure 7A, binding of 
p85-PI3K to GST-RARα could not be 
detected, independently of the presence of RA. 
As positive control experiment, the assay 
readily detected the interaction of GST-RARα 
and RXRα, which are known to form 
heterodimers in vitro (22). Consistently with 
that, immunoprecipitation experiments 
performed after co-transfection of expression 
plasmids for RARα and p85α-HA into COS-7 
cells did not resulted in the formation of a 
binary complex (Fig. 7B). Although most of 
p85-PI3K was in the precipitated fraction, 
RARα was recovered quantitatively from the 
supernatant of the immunoprecipitation. Taken 
together, the results pointed out that the 
interaction between RAR and p85-PI3K is not 
direct. Therefore, other yet unknown proteins 
mediating or stabilizing RAR-p85 interactions 
may be involved in complex formation, which 
may became limiting in overexpression 
experiments.  
 
Influence of RAR intracellular localization 
on RA-induced PI3K activation.  
 
A paradox arises from the fact that 
PI3K activity takes place at the plasma 
membrane, whereas RAR, as other members 
of the nuclear receptor superfamily, is located 
mainly in the nucleus. Therefore, intracellular 
localization of RAR might be relevant for RA-
induced activation of PI3K. To address this 
point, we have examined whether ectopic 
localization of RAR at plasma membrane 
would affect the activation of PI3K by RA. 
For this purpose we have constructed a 
chimerical receptor fusing c-Src myristylation 
domain (23) to the N-terminus of RARα (Myr-
RARα). We have overexpressed this 
chimerical Myr-RARα and wild-type RARα in 
NIH-3T3 cells through retroviral vectors, and 
examined their intracellular localization in 
conventional cell fractionation experiments. 
The results showed that most of the Myr-
RARα receptor could be located in the nuclear 
fraction, as was the case for wild-type RARα. 
However, considerable amounts of Myr-RARα 
could be detected in the microsomal fraction 
and in purified plasma membrane, whereas 
wild-type RARα was not detected in 
membrane fractions (Fig. 8A). In detergent-
partition experiments Myr-RARα receptor 
could be detected in the detergent-resistant 
fraction, whereas wild type RARα could not 
(data not shown). As compared to those of 
wild type RARα, the levels of Myr-RARα 
receptor were strongly increased in detergent-
resistant membrane microdomain fractions 
(lipid rafts), co-migrating with caveolin 1 in 
sucrose gradients (Fig. 8B). Therefore, these 
experiments demonstrated that Myr-RARα 
receptor shows increased presence in plasma 
membrane fractions, as compared to wild-type 
RARα.  
The ability of Myr-RARα receptor to 
activate PI3K signaling pathway was tested in 
retrovirally transfected MEF(RARαβγ)L-/L- 
cells. As compared to wild-type RARα, Myr-
RARα was a potent activator of PI3K in the 
absence of RA, and surprisingly the addition 
of RA did not further increased PI3K activity 
(Fig. 8C). Similar results were obtained in 
transient transfection experiments in COS-7 
cells (Fig. 8D). These results showed that the 
presence of the receptor at the plasma 
membrane results in increased activation of 
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PI3K, although in those conditions binding of 
the ligand appears to be dispensable.  
The above results are compatible with 
a model in which the binding of the ligand 
may play a role in the localization of RAR to 
the plasma membrane, allowing there 
interactions with components of the signal 
transduction machinery leading to PI3K 
activation. To test that hypothesis we have 
examined the intracellular location of RAR. 
Attempts to show the presence of RAR in 
plasma membrane from SH-SY5Y or NIH-
3T3 cells by immunofluorescent confocal 
microscopy with a variety of commercially 
available anti-RAR antibodies failed (data not 
shown). A Green Fluorescent Protein-tagged 
RARα version (GFP-RARα) was generated, 
and its expression vector was transiently or 
stably transfected to COS-7 cells. When 
analyzed by fluorescent confocal microscopy, 
the cells showed strong nuclear staining with 
few cells showing plasma membrane 
localization of GFP-RARα fusion protein. 
However, a consistent plasma membrane 
pattern could not be detected, and the addition 
of RA did not affected GFP-RARα 
intracellular distribution (data not shown). As 
alternative approach, we have analyzed the 
distribution of endogenous RARα in SH-
SY5Y neuroblastoma cells by means of 
conventional biochemical cell fractionation 
experiments. RARα could not be detected in 
microsomal or purified plasma membrane 
fractions by western blot immunodetection 
(data not shown). Similar fractionation 
experiments were performed in NIH-3T3 cells. 
As expected, most of the RARγ receptor was 
detected in the nuclear fraction. 
Administration of RA to NIH-3T3 cells 
resulted in a strong increase in the levels of 
RARγ into the membrane fractions 
(microsomal and purified plasma membranes) 
(Fig. 9A). Similarly, RARα-p85 complexes 
could be detected in the microsomal fraction 
of SH-SY5Y neuroblastoma cells, in 
experiments involving a combination of cell 
fractionation and immunoprecipitation. A RA-
induced increase in the levels of those 
complexes in membrane fractions could be 
observed (Fig. 9B). Both experiments suggest 
the idea of a ligand-induced redistribution of 
the receptor to plasma membrane.  
 
 
DISCUSSION 
Although the classical transcriptional 
effects of RA have been extensively studied 
((4, 24), for recent reviews), little information 
is available about the non-classical, rapid non-
genomic effects of RA on signal transduction 
pathways and their physiological implications. 
A considerable amount of information on non-
genomic actions of steroid hormones has 
accumulated during the last few years ((6-8, 
25), for recent reviews), but only a few 
examples of non-genomic actions of RA have 
been reported (14, 18, 26-34).  
We have obtained insight into the 
mechanistic of activation of PI3K by RA, and 
the results reported here support a novel 
mechanism, in which a stable complex 
including RAR, the regulatory subunit p85-
PI3K and other unknown proteins occurs in 
the absence of RA. Ligand binding to RAR 
facilitates the association of p110, the catalytic 
subunit of PI3K, to that complex, and 
therefore promoting PI3K activity. In addition, 
we have shown experiments suggesting a role 
for RA in the regulation of the intracellular 
location of that signaling complex that could 
be relevant for PI3K activation, and 
recruitment of the signaling complex to plasma 
membrane resulted in increased PI3K activity. 
We believe that this novel mechanism could 
be extended to other members of the Nuclear 
Receptor superfamily, especially for those 
belonging to the retinoic/thyroid hormone 
/vitamin D subfamily of receptors.  
The involvement of the classical 
nuclear hormone receptors in the non-genomic 
actions of steroid hormones and other ligands 
has been controversial over the past decade. 
However considerable evidence has 
accumulated supporting that nuclear hormone 
receptors are also responsible of the rapid non-
genomic actions of steroid hormones, 
especially for ER (35-39). The participation of 
nuclear RA receptor RAR in RA-mediated non 
genomic actions is supported by the 
pharmacological profile of PI3K activation, by 
loss and gain function experiments performed 
in MEF(RARαβγ)L-/L- cells, and by the 
physical association between liganded RARα 
and PI3K activity, as demonstrated in 
immunoprecipitation/PI3K assays. Although 
the failure of the RAR antagonist AGN193109 
in preventing the activation of PI3K by RA or 
TTNPB could argue against the participation 
of RAR, AGN193109 itself is able to activate 
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PI3K, suggesting a dissociated transcriptional 
antagonist/non-genomic agonist profile, as has 
been reported for other compounds like the 
specific ER modulators estren and raloxifen, 
(40, 41), or synthetic vitamin D3 analogs (42).  
PI3K is an important signaling node 
on the control of a variety of cellular 
responses, including survival, growth and 
differentiation ((43) for review). The 
mechanism depicted here involves RA-
induced formation of a signaling complex, 
probably through stimulation of the 
association of p85 and p110 subunits of PI3K. 
The impact of the regulatory subunit p85 on 
PI3K activity has been controversial, and 
evidences supporting both positive and 
negative effect of p85 on PI3K activity exist in 
the literature (44, 45). Our results suggest that 
heterodimer formation between p85 and p110 
result in increased PI3K activity. In addition, 
recruitment of p110 subunit to plasma 
membrane in the proximity of its substrate 
could affect its activation, as previously 
reported (46). A mechanism involving Cellular 
Retinol-Binding Protein I (CRBP-I) in the 
regulation of PI3K subunit heterodimerization 
has been reported recently in breast cancer 
cells, where RA signaling would have negative 
effects on PI3K subunit association and PI3K 
activity. However, the different context 
between adoptive long-term effects (47) and 
the rapid effects analyzed here could account 
for the controversy.  
The presence of steroid hormone 
receptors at the plasma membrane and in 
caveolae and its importance for the cellular 
effects of steroid hormones are increasingly 
accepted. However how the receptors are 
tethered to the membrane is still unclear, 
although the few reports addressing this point 
suggest that membrane localization could 
result from receptor interaction with specific 
membrane proteins and/or lipid modifications 
(for review see (25)). Because RAR, as other 
members of the nuclear receptor superfamily, 
is located mainly in the nucleus, an intriguing 
paradox arises from the fact that rapid non 
genomic actions of nuclear receptors appear to 
be initiated at the plasma membrane. Any 
model wanting to explain the mechanism of 
PI3K activation by RAR needs to address this 
point. The importance of the localization of the 
receptor at the plasma membrane became 
evident because ectopic expression of RARα 
to plasma membrane by the introduction of a 
myristylation domain resulted in increased 
PI3K activation. Increased non-genomic 
signaling was also observed by targeting ER to 
the plasma membrane, but full activation 
required the addition of hormone (48). 
Conversely, chimerical or mutant ER with 
reduced plasma membrane localization show 
reduced non-genomic activity (40, 49, 50) 
Some experiments shown here suggest that 
ligand binding may control the localization of 
the receptor, promoting the presence of ligand-
bound RAR at the plasma membrane. 
However, we have failed to obtain formal 
demonstration for this hypothesis by confocal 
microscopy. Probably only a minor part of the 
RAR pool is engaged in non-genomic actions 
(less than 5%, as estimated from 
immunoprecipitation experiments). This could 
be close to the threshold level for conventional 
detection methodologies. As suggested here 
for RAR, a rapid ligand-induced association of 
Vitamin D3 receptor to plasma membrane has 
been also reported (51, 52).  
The mechanism proposed here shows 
striking differences with the prevalent model 
proposed to explain the non genomic actions 
of steroid receptors as the ER (for a review 
(25)). In that case a pool of resident plasma 
membrane ER molecules interact there with 
the components of the signal transduction 
machinery in a way that those interactions are 
under the control of the ligand, as described 
for the interactions between ER, GR or AR 
and p85, the regulatory subunit of PI3K (15-
17, 53). The different dynamics of the two 
subfamilies of nuclear hormone receptors and 
their peculiarities may have imposed different 
regulatory solutions to ultimately obtain the 
ligand-dependent regulation of PI3K 
activation. The unliganded receptors of the 
retinoic/thyroid subfamily are mainly nuclear 
and they don’t form inactive complexes with 
hsp90 and other proteins. A stable interaction 
of p85-PI3K with the receptor, shown here for 
RAR, was recently reported for thyroid 
hormone receptor (54, 55). If the presence of 
the complex including the receptor and p85-
PI3K at the plasma membrane may increase 
upon ligand binding, as indicated by the 
experiments shown here, this may facilitate the 
recruitment of the catalytic subunit p110-PI3K 
to the complex and could allow interactions 
with other components of the signal 
transduction machinery. On the contrary, 
unliganded steroid receptors form inactive 
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complex with hsp90 and other proteins that 
keep the receptor in an inactive form. It 
appears conceivable that these interactions 
with hsp90 and/or other of the proteins within 
the unliganded steroid receptor complex could 
preclude an interaction with p85-PI3K, which 
only takes place once the complex is 
dissociated upon ligand binding.  
 
MATERIAL AND METHODS 
Cell Culture and treatments.  
SH-SY5Y human neuroblastoma cells, COS-7 
cells, MEF-wt, MEF(RARαβγ)L-/L- cells and 
BOSC23 cells were cultured in DMEM 
medium with 10% fetal calf serum, 100 
units/ml penicillin and 100 µg/ml 
streptomycin. NIH-3T3 cells were cultured in 
DMEM medium with 10% newborn calf 
serum, 100 units/ml penicillin and 100 µg/ml 
streptomycin. Cell cultures were kept in a 
humidified incubator at 37ºC with 5% CO2. 
The medium was replaced every 3 days and 
the cells were split before they reached 
confluence. Cycloheximide (CHX) 
Actinomycin D (AMD), Puromycin, 
LY294002,  all-trans-retinoic acid (RA), 9-
cis-retinoic acid (9-c-RA), 13-cis-retinoic acid 
(13-c-RA), TTNPB, Am580, and N-(4-
Hydroxyphenyl)-retinamide (4-HPR, 
fenretinide) were purchased from Sigma. 
AGN193109 (UVI2109) (20), ALRT1550 
(UVI2103) (56), and LG100567 (UVI2104) 
(57) were synthesized and their spectroscopic 
and analytical data matched those reported in 
the literature. The different compounds were 
dissolved in ethanol or DMSO and added to 
the culture medium at the indicated 
concentrations.  
 
RNA analysis 
Northern Blot analysis of total RNA from SH-
SY5Y cells with a [32P]-labeled probe was 
performed as previously described (14). RARB 
probe consisted in a 1.4 kb DNA fragment 
containing the human RARβ2 cDNA (58).  
 
Western Blot and Immunoprecipitation 
Whole cell extracts were obtained by lysis of 
the cells in RIPA buffer (50 mM Hepes pH 
7.4, 150 mM NaCl, 1 mM EGTA) containing 
0.5% Nonidet P-40, protease (1 mM PMSF, 10 
µg/ml aprotinin and 10 µg/ml leupeptin) and 
phosphatase inhibitors (1 mM sodium 
ortovanadate, 1 mM NaF). After 10 min 
incubation on ice, the lysate was cleared by 
centrifugation (16,100 g, 10 min, 4ºC), and 
protein concentration determined. Western 
blot analysis of proteins from whole cell 
extracts was performed as described (14). 
Antibodies against, RARα, RARγ, 
RXRα, Caveolin 1, ERK2, Akt 1/2, and the 
phosphorylated (Tyr204) form of ERK1/2 were 
purchased from Santa Cruz Biotechnology. 
Antibodies against phosphorylated Akt 
(Ser473), RARα and Lamin A were obtained 
from Cell Signal Technologies. Antibodies 
against PI3K-p85 and –p110 were from 
Upstate. HA.11 monoclonal antibody was 
purchased from Covance. Monoclonal 
antibody against p110-PI3K was a gift of Dr. 
A. C. Carrera (CNB, CSIC-UAM, Madrid). 
Horseradish-peroxidase-conjugated secondary 
antibodies were obtained from GE Healthcare, 
Jackson ImmunoResearch and Santa Cruz 
Biotechnology. Chemiluminiscent signals 
were developed with ECL or ECL Plus (GE 
Healthcare).  
For immunoprecipitation cells were treated 
with RA (1 µM, 10 min) or vehicle and cell 
extracts prepared in 50 mM Tris-HCl pH 8, 
150 mM NaCl, 1% Nonidet P-40, and protease 
(1 mM PMSF, 40 µg/ml aprotinin and 40 
µg/ml leupeptin) and phosphatase inhibitors (1 
mM sodium ortovanadate, 1 mM NaF). 
Alternatively, nuclear extract or microsomal 
fractions were prepared as described below in 
Subcellular Fractionation. Approximately 150 
µg protein from control or RA-treated cell 
extracts were incubated with 5 µg of 
antibodies against p85-PI3K, RARα, or p110-
PI3K as indicated. As control, parallel 
reactions were set with an unrelated antibody. 
Immunocomplexes were precipitated using 
anti-rabbit IgG beads (eBioscience), following 
the manufacturer’s instructions, and suspended 
in sample buffer containing freshly added 50 
mM DTT. After Western blot as above, the 
filters were sequentially developed with the 
antibodies indicated in the figure, using 
Horseradish-peroxidase-conjugated Rabbit 
TrueBlot (eBioscience) as secondary 
antibodies. Chemiluminiscent signals were 
developed with ECL (GE Healthcare). 
 
GST pull-down assay 
GST-RARα  (59) was expressed in E. coli 
BL21 cells and purified by using standard 
techniques. For the pull-down assays, 20 ng of 
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GST-RARα or GST protein immobilized in 
glutathione-agarose beads were added to cell 
lysates (160 µg protein) from COS-7 cells 
expressing p85-PI3K-HA or RXRα in 500 µl 
of 50 mM Tris pH 7.5, 150 mM Nacl, 10% 
Glycerol, 1% Nonidet P-40, 1 mM PMSF, 40 
µg/ml aprotinin, 40 µg/ml leupeptin, 10 µg/ml 
pepstatin, 1 mM NaF and 1 mM sodium 
ortovanadate. Extract from non-transfected 
COS-7 cells was used as negative control. 
Where indicated, 1 µM RA was included in the 
incubation mixture. After incubation (18 h, 
4ºC), the beads were washed three times with 
the same buffer, and the bound proteins 
detected by Western blot.  
 
PI3K Assay 
Extracts from control or RA-treated (1µM RA, 
10 min) SH-SY5Y cells, containing 150 µg 
protein were incubated with 5 µg of RARα 
antibodies, p110-PI3K antibodies or an 
unrelated control IgG, and the 
immunocomplexes recovered with protein A/G 
Plus-Agarose (Santa Cruz Biotecnology). The 
complexes were washed 3 times with 10 mM 
Hepes, pH 7.5, 0.1 mM EGTA. Kinase 
reactions were set by mixing 20 µl 
immunoprecipitates, 20 µl of 0.5 mg/ml L-α-
phosphatidyl-inositol (Sigma) in 10 mM 
HEPES pH 7.4, 0.1 mM EGTA and 10 µl of 
50 mM HEPES pH 7.4, 25 mM MgCl2 
containing 10 µCi of [γ-32P]-ATP (NEN, spec. 
act 3000 Ci/mmol). Kinase assays were 
performed as described (14). Quantification of 
the radioactivity on the spots was carried out 
with Phosphor capture screens in a Fujifilm 
FLA5000 laser scanner.  
 
Transient and retrovirus-mediated 
transfection 
Myr-RARα expression vector was generated 
by in-frame fusion of RARα (2-462) to the 21 
residues of the chick c-Src myristylation 
domain present in pCEFL-Myr expression 
vector (a gift of Dr. P. Crespo, IIB-Univ. de 
Cantabria). Semi-confluent COS-7 cells were 
transfected by the Calcium Phosphate method 
with expression vectors for RARα and Myr-
RARα. After 8-14 h of exposure to the 
precipitates, the medium was replenished. RA 
treatments took place after 24 h, and cells were 
lysed and cell extracts processed for Western 
Blotting. Retroviral particles for the expression 
of RARα and Myr-RARα and its derivatives 
were prepared by transfecting retroviral vector 
expression vectors based on pBABE (60) into 
BOSC23 packaging cells (61) by the Calcium 
Phosphate method. After 2 days of incubation, 
the supernatants containing retrovirus were 
used to infect semi-confluent MEF(RARαβγ)L-
/L- or NIH-3T3 cells, and pools of transfected 
cells were selected with Puromycin (2.5 
µg/ml). For immunoprecipitation, semi-
confluent COS-7 cells were co-transfected 
with expression vectors for hRARα and p85-
PI3K-HA (62) by the Calcium Phosphate 
method. After 8-14 h of exposure to the 
precipitates, the medium was replenished, and 
after further 24 h the cells were lysed and cell 
extracts processed for immunoprecipitation. 
 
Subcellular  fractionation 
Membrane fractions were obtained according 
to (52) with some modifications. SH-SY5Y 
neuroblastoma cells, wild-type or retrovirally 
transfected NIH-3T3 cells cells overexpressing 
RARα or Myr-RARα were washed with PBS 
and harvested. Cells were pelleted by 
centrifugation and resuspended in TEDK 
buffer (10 mM Tris-HCl, pH 7.4; 0.3 M KCl, 1 
mM EDTA, 1mM DTT) containing protease 
(1 mM PMSF, 40 µg/ml aprotinin, 40 µg/ml 
leupeptin) and phosphatase inhibitors (1 mM 
sodium ortovanadate, 1 mM NaF). Cell 
suspension was homogenized in a glass-teflon 
homogenizer and the lysate was centrifuged 
first at 200 g for 10 min to eliminate cell 
debris, and later to 16,100 g for 20 min to 
pellet the nuclei and mitochondria. The cleared 
lysate was centrifuged at 100,000 g for 45 min. 
in a Beckmann SW60 rotor. The pellet 
containing the microsomal fraction was 
resuspended in 1.5 ml of TEDK containing 
15% sucrose and laid on top of a 30-45% 
sucrose step gradient. Gradients were run at 
76,000 g for 3 h and the interface between 15-
30% sucrose, containing purified plasma 
membranes, was picked up, diluted in TEDK 
and the membranes re-pelleted at 100,000 g 
for 1 h. The purified plasma membrane was 
resuspended in TEDK buffer containing 
inhibitors.  
Nuclear fraction was obtained resuspending 
cells in 60 mM KCl, 15 mM NaCl, 20 mM 
Tris-HCl pH 8, 0.15 mM spermine, 0.5 mM 
spermidine, 2 mM EDTA, 0.5 mM EGTA. 
Cell suspension was mixed with one volume 
of the same buffer containing 0.5% Nonidet P-
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40 and incubated for 5 min on ice. Nuclei were 
pelleted by centrifugation at 1,500 g for 10 
min at 4ºC, and washed with the same buffer 
without detergent. The Nuclei were re-pelleted 
and lysated with RIPA buffer containing 0.5% 
Nonidet P-40, 1% sodium deoxycholate, and 
0.1% SDS.  
Detergent-resistant membrane microdomains 
(lipid rafts) from NIH-3T3 cells 
overexpressing RARα and Myr-RARα were 
fractionated in sucrose step-gradients as 
previously described (63, 64), with 
modifications. About 15 x106 cells were 
suspended in 500 µl of ice-cold lysis buffer 
(25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 
mM EDTA, 0.25% TritonX-100) plus 
inhibitors (1 mM PMSF, 40 µg/ml aprotinin, 
40 µg/ml leupeptin, 1 mM sodium 
ortovanadate, 1 mM NaF) and solubilized for 
30 min at 4 °C. Sucrose concentration of the 
lysates was adjusted to 41% before they were 
overlaid with 2.7 ml of 35% sucrose and 0.8 
ml of 16% sucrose prepared in 10 mM Tris-
HCl, pH 7.4. Sucrose gradients were 
ultracentrifuged (40,000 rpm in a SW60 rotor, 
18 h, 4 °C), and 10 0.4 ml fractions were 
collected from each gradient (from the top to 
the bottom, fractions 1–10; fraction 10 
included the pellet), precipitated with 6.5% 
trichloroacetic acid in the presence of 0.05% 
sodium deoxycholate, washed with 80% cold 
acetone, dissolved, and boiled in 2x Laemmli 
sample buffer. Fractions were analyzed by 
SDS-PAGE followed by Western blotting. 
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LEGEND TO FIGURES 
 
Figure 1. Rapid, non-genomic activation of PI3K/Akt and ERK1/-2 signaling pathways by RA 
treatment in SH-SY5Y neuroblastoma cells  
A. Rapid activation of PI3K signaling pathway by RA. Cells were treated with RA (1 µM) for the 
times indicated in the figure and total cell extracts were prepared. The phosphorylation state of Akt 
was analyzed by Western Blot with specific antibodies against Akt phosphorylated in Ser473 (AKT-
P). The filter was reprobed with antibodies against total Akt (AKT). Each lane contains 25 µg of 
total protein.  
B. Rapid activation of PI3K by RA did not required new gene transcription or newly synthesized 
proteins. Neuroblastoma cells were pre-treated for 30 min with the protein synthesis inhibitor 
Cycloheximide (CHX, 10 µg/ml) or the transcription inhibitor Actinomycin D (AMD, 1 µg/ml). 
Afterwards they were treated with RA (1µM) or vehicle for 5 min, and the phosphorylation state of 
Akt was analyzed by Western Blot as described in the legend of Fig. 1A.  
C. Rapid activation of ERK1/2 signaling pathway by RA. Cells were treated with RA (1µM) for the 
times shown in the figure and total cell extracts were prepared. The phosphorylation state of 
ERK1/2 MAP kinases was analyzed by Western Blot with specific antibodies against the 
phosphorylated (Tyr204) form of ERK 1/2 (ERK-P). The filter was reprobed with antibodies against 
ERK2 (ERK2). Each lane contains 25 µg of total protein.  
 
Figure 2. Activation of PI3K/Akt and ERK1/2 signaling pathways by RA in NIH-3T3 cells  
A. RARγ is expressed in NIH-3T3 cells. RARγ (approximately 50 KDa, arrow) was detected in 
total cell extract by Western Blot with specific antibodies. The positions of the corresponding 
marker bands and their molecular weights (in KDa) are shown on the left side of the blot. Gel lane 
contained 25 µg total proteins.  
B. Rapid activation of PI3K by RA in NIH-3T3 cells. Cells were serum-starved for 14 h and then 
treated with RA (1µM) for the times indicated. The phosphorylation state of Akt was analyzed by 
Western Blot as described in the legend of Fig. 1A. 
C. Rapid activation of PI3K by RA did not required new gene transcription or newly synthesized 
proteins. NIH-3T3 cells were pre-treated for 30 min with the transcription inhibitor Actinomycin D 
(AMD, 1 µg/ml), the protein synthesis inhibitor Cycloheximide (CHX, 10 µg/ml), or the PI3K 
specific inhibitor LY294002 (LY, 10 µM). Afterwards they were treated with RA (1µM) or vehicle 
for 10 min, and the phosphorylation state of Akt was analyzed by Western Blot as described in the 
legend of Fig. 1A.  
D. Rapid activation of ERK1/2 signaling pathway by RA in NIH-3T3 cells. Cells were serum-
starved for 14 h and then treated with RA (1µM) for the times indicated. Total cell extracts were 
prepared, and the phosphorylation state of ERK1/2 MAP kinases was analyzed by Western Blot as 
described in the legend of Fig. 1C.  
 
Figure 3. Pharmacological profile of the activation of the PI3K/Akt signaling pathway by RA 
and its derivatives in neuroblastoma cells  
A. Neuroblastoma cells were treated during 10 min with different RA concentrations as indicated in 
the figure, and the phosphorylation state of Akt was analyzed by Western Blot as described in the 
legend of Fig. 1A. 
B. Activation of PI3K by different RAR agonists. Neuroblastoma cells were treated during 10 min 
with all-trans-RA (RA), 9-cis-RA (9c-RA), 13-cis-RA (13c-RA), TTNPB, Am580, N-(4-
Hydroxyphenyl)-retinamide (fenretinide, 4-HPR), ALRT1550 (ALRT), and LG100567 (LG) at 1 
µM. Afterwards, the phosphorylation state of Akt was analyzed by Western Blot as described in the 
legend of Fig. 1A.  
C. Effect of the RAR transcriptional antagonist AGN193109 on the activation of PI3K by RAR 
agonists. Neuroblastoma cells were treated during 10 min with 0.5 µM RA (RA), 0.5 µM TTNPB 
(TTNPB), 0.5 µM RA and 5 µM AGN193109 (RA+AGN), 0.5 µM TTNPB and 5 µM AGN193109 
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(TTNPB+AGN), and 5 µM AGN193109 alone (AGN). Afterwards, the phosphorylation state of 
Akt was analyzed by Western Blot as described in the legend of Fig. 1A. 
D. As a control, the effect of the RAR antagonist AGN193109 on the transcriptional induction of 
RARB, encoding the RARβ receptor, in neuroblastoma cells was tested. Cells were treated with 0.5 
µM RA (RA), or 0.5 µM RA and 5 µM AGN193109 (RA+AGN) during 24 h. Afterwards, total 
RNA was prepared and the expression of RARB transcript (approximately 3 Kb) was analyzed by 
Northern Blot with a [32P]-labeled RARB probe. Each lane contained 15 µg of total RNA. The 28S 
ribosomal RNA band in the blot stained with methylene blue is shown as internal loading control 
(rRNA).  
 
Figure 4. RA-induced PI3K activation was abolished in RAR null MEF cells, but was restored 
by re-introduction of RAR expression.  
A. RA treatment rapidly activates PI3K in wild-type MEF cells. Wild-type MEF cells were serum-
starved for 14 h, treated with 1 µM RA for the times indicated on the figure and total cell extracts 
were prepared. The phosphorylation state of Akt was analyzed by Western Blot as described in the 
legend of Fig. 1A.  
B. RA-induced PI3K activation is abolished in MEF(RARαβγ)L-/L- cells. MEF(RARαβγ)L-/L- cells 
were serum-starved for 14 h, treated with 1 µM RA for the times indicated on the figure and total 
cell extracts were prepared. As control for the integrity of the PI3K signaling pathway, cells were 
serum-stimulated with 10% FBS for 10 min. (lane labeled SE). The phosphorylation state of Akt 
was analyzed by Western Blot as described in the legend of Fig. 1A.  
C. Retrovirus-mediated re-expression of RARα restored RA-induced PI3K activation. 
MEF(RARαβγ)L-/L- cells and a derivative cell line expressing RARα through retroviral transfection, 
MEF(RARαβγ)L-/L-+RARα, were serum-starved for 14 h, treated with 1 µM RA for the times 
indicated on the figure and total cell extracts were prepared. The phosphorylation state of Akt was 
analyzed by Western Blot as described in the legend of Fig. 1A.The filter was reprobed additionally 
with antibodies against RARα. 
 
Figure 5. PI3K activity was physically associated to ligand-bound RARα.  
PI3K activity was assayed in vitro on immunoprecipitated fractions of control (-) and RA-treated (1 
µM, 10 min.) (+) SH-SY5Y neuroblastoma cells. Immunoprecipitation reactions were set with anti-
RARα and anti-p110-PI3K antibodies, and parallel control reactions with a non-related antibody (n. 
r.) were set as controls. PI3K activity was assayed on the immunoprecipitates in the presence of 
Phosphatidyl-inositol and [γ-32P]-ATP as described in the Material and Methods section. The 
caption shows a detail of the autoradiogram of the thin layer chromatography plate showing the 
generation of Phosphatidyl-inositol-3-phosphate (PIP) in vitro. Activity data (in arbitrary units) 
were obtained by quantification of the radioactivity in the spots with Phosphor capture screens in a 
Fujifilm FLA5000 laser scanner. 
 
Figure 6. Interactions between RARα and PI3K subunits.  
A. Total cell extracts were prepared from neuroblastoma cells treated with 1µM RA or vehicle for 
10 min. About 150 µg protein from control or RA-treated cell extracts were incubated with 5 µg of 
RARα antibody. As control, parallel reactions were set with an unrelated antibody. 
Immunocomplexes were precipitated using anti-rabbit IgG beads (eBioscience), following the 
manufacturer’s instructions, and suspended in sample buffer containing freshly added 50 mM DTT. 
After Western blot the filter was sequentially developed with anti-p85-PI3K and anti-RARα, using 
Horseradish-peroxidase-conjugated Rabbit TrueBlot (eBioscience) as secondary antibodies. The 
filter was reprobed additionally with an anti-p110-PI3K monoclonal antibody. Note the anomalous 
migration of RARα (approx. 50 KDa) in the immunoprecipitate lanes, that is due to co-migration 
with IgG heavy chain (approx. 50 KDa), which in its reduced form was not detected by the 
TrueBlot secondary antibodies.  
B. Total cell extracts were prepared from neuroblastoma cells treated with 1µM RA or vehicle for 
10 min. About 150 µg protein from control or RA-treated cell extracts were incubated with 5 µg of 
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p85-PI3K antibody. As control, parallel reactions were set with an unrelated antibody. 
Immunocomplexes were precipitated as described in the legend of Fig. 6A. After Western blot, the 
filters were sequentially developed with anti-RARα and anti-p85-PI3K, using Horseradish-
peroxidase-conjugated Rabbit TrueBlot (eBioscience) as secondary antibodies. Note the anomalous 
migration of RARα (approx. 50 KDa) in the immunoprecipitate lanes, that is due to co-migration 
with IgG heavy chain (approx. 50 KDa), which in its reduced form was not detected by the 
TrueBlot secondary antibodies. 
C. Nuclear extract was prepared from untreated neuroblastoma cells, and 150 µg protein from 
nuclear extract were incubated with 5 µg of p85-PI3K antibody. As control, a parallel reaction was 
set with an unrelated antibody. Immunocomplexes were precipitated and Western Blot was carried 
out as described in the legend of Fig. 6A. Note the anomalous migration of RARα (approx. 50 
KDa) in the immunoprecipitate lanes, that is due to co-migration with IgG heavy chain (approx. 50 
KDa), which in its reduced form was not detected by the TrueBlot secondary antibodies 
D. RA administration increases association of p110-PI3K to RARα-p85-PI3K complex in 
neuroblastoma cells. Total cell extracts were prepared from neuroblastoma cells treated with 1µM 
RA or vehicle for 10 min. About 150 µg protein from control or RA-treated cell extracts were 
incubated with 5 µg of p110-PI3K antibody. As control, parallel reactions were set with an 
unrelated antibody. Immunocomplexes were precipitated as described in the legend of Fig. 6A. 
After Western blot, the filters were sequentially developed with anti-RARα and anti-p85-PI3K 
using Horseradish-peroxidase-conjugated Rabbit TrueBlot (eBioscience) as secondary antibodies. 
Note the anomalous migration of RARα (approx. 50 KDa) in the immunoprecipitate lanes, that is 
due to co-migration with IgG heavy chain (approx. 50 KDa), which in its reduced form was not 
detected by the TrueBlot secondary antibodies. 
 
Figure 7. The interaction between RAR and p85-PI3K does not appear to be direct.  
A. RARα and p85-PI3K do not interact in vitro in GST pull-down assays. Recombinant GST-
RARα and GST protein were expressed in E. coli and bound to glutathione-agarose beads. GST-
RARα or GST beads were incubated with cell lysates of COS-7 cells expressing p85-PI3K-HA 
(HA-p85) or human RXRα (RXRα). Extract from non transfected cells is used as negative control 
(C). Where indicated 1 µM RA (+) or vehicle (-) was added to the pull-down reaction. Bound 
proteins were detected by Western Blot, and the filter sequentially developed with anti-HA and anti-
RXRα antibodies. For comparison, the amount of extracts loaded in the lanes labeled input 
corresponds to 25% of the amount loaded from the pull-down assays.  
B. RARα and p85-PI3K did not form a complex when co-expressed in COS-7 cells. COS-7 cells 
were co-transfected with RARα and p85-HA expression plasmids. Total cell extract (150 µg 
protein) was incubated with 5 µg of anti-p85-PI3K antibody. As control a parallel 
immunoprecipitation was set with an unrelated IgG (n. r.). Immunocomplexes were precipitated as 
described in the legend of Fig. 6A. The supernatant of the p85 immunoprecipitation (snat) was also 
included in the gel After Western blot, the filters were sequentially developed with anti-RARα and 
anti-p85-PI3K, using Horseradish-peroxidase-conjugated Rabbit TrueBlot (eBioscience) as 
secondary antibodies. Note the anomalous migration of RARα (approx. 50 KDa) in the 
immunoprecipitate lanes, that is due to co-migration with IgG heavy chain (approx. 50 KDa), which 
in its reduced form was not detected by the TrueBlot secondary antibodies. 
 
Figure 8. Ectopic expression of RARα in the plasma membrane results in increased activation 
of the PI3K/Akt signaling pathway.  
A. Myr-RARα is targeted to plasma membrane. Whole cell extract, nuclear fraction, microsomal 
fraction, and plasma membrane fraction purified from sucrose gradients were obtained from 
retrovirally transfected NIH-3T3 cells overexpressing wild type RARα or Myr-RARα chimerical 
receptor. RARα and Myr-RARα were detected by Western Blot with antibodies against RARα. 
Equal amounts of protein from RARα- and Myr-RARα-expressing cells were loaded.  
B. Myr-RARα localizes in detergent-resistant membrane micro domains (lipid rafts). TritonX-100 
extracts from NIH-3T3 cells overexpressing RARα and Myr-RARα were fractionated in parallel 
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sucrose step-gradients as described in the Material and Methods section. Fractions were collected 
from each gradient (10 0.4 ml fractions from the top to the bottom, fractions 1–10; fraction 10 
included the pellet). The presence of RARα in total cell extract (T) and the different fractions (1-10) 
was analyzed by Western Blotting with specific antibodies. The filter was reproved with antibodies 
against Caveolin-1 (cav1) to mark the low-density lipid rafts-containing fractions.  
C. Expression of Myr-RARα increases the activity of PI3K/Akt signaling pathway. Parental 
MEF(RARαβγ)L-/L- cells and its derivatives expressing RARα and Myr-RARα through retroviral 
vectors were serum-starved for 14 h, treated with vehicle (-) or RA (1 µM, 10 min)(+) as indicated 
on the figure and total cell extracts were prepared. The phosphorylation state of Akt was analyzed 
by Western Blot as described in the legend of Fig. 1A.The filter was reprobed additionally with 
antibodies against RARα. 
D. Transfection of Myr-RARα increases the activity of PI3K/Akt signaling pathway. COS-7 cells 
were transfected with expression vectors encoding RARα, Myr-RARα or empty vector (mock) by 
the calcium phosphate protocol. Medium was replenished after transfection and 24 h later the cells 
were treated with vehicle or 1 µM RA for 10 min. Total cell extracts were prepared and the 
phosphorylation state of Akt was analyzed by Western Blot as described in the legend of Fig. 1A. 
The filter was reprobed additionally with antibodies against RARα. 
 
Figure 9. Ligand-induced localization of RAR to Plasma Membrane.  
A. Liganded RARγ is targeted to plasma membrane in RA-treated NIH-3T3 cells. Cells were treated 
with vehicle (-) or 1 µM RA (+) for 10 min. Whole cell extract, nuclear fraction, microsomal 
fraction, and plasma membrane fraction purified from sucrose gradients were obtained as described 
in the Material and Methods section and analyzed by Western Blotting. Equal amounts of protein 
from untreated and RA-treated cells were loaded. The filters were probed sequentially with 
antibodies against RARγ, Caveolin-1 (Cav1) and Lamin A (LamA). (n.d., not done).  
B. Detection of RARα-p85 complexes in membrane fractions from SH-SY5Y cells. Microsomal 
fractions were prepared from neuroblastoma cells treated for 10 min with 1µM RA (+) or vehicle (-
). About 150 µg protein from microsomal fractions from control or RA-treated cells were incubated 
with 5 µg of p85-PI3K antibodies as indicated. Immunocomplexes were precipitated as described in 
the legend of Fig. 6A. After Western blot, the filters were sequentially developed with anti-RARα 
and anti-p85-PI3K, using Horseradish-peroxidase-conjugated Rabbit TrueBlot (eBioscience) as 
secondary antibodies. Note the anomalous migration of RARα (approx. 50 KDa) in the 
immunoprecipitate lanes, that is due to co-migration with IgG heavy chain (approx. 50 KDa), which 
in its reduced form was not detected by the TrueBlot secondary antibodies. Total cell extract from 
SH-SY5Y cells was included as reference (T): 
 
 









